Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Total Liabilities (2017 - 2025)

Arcus Biosciences has reported Total Liabilities over the past 9 years, most recently at $508.0 million for Q4 2025.

  • Quarterly results put Total Liabilities at $508.0 million for Q4 2025, down 23.61% from a year ago — trailing twelve months through Dec 2025 was $508.0 million (down 23.61% YoY), and the annual figure for FY2025 was $508.0 million, down 23.61%.
  • Total Liabilities for Q4 2025 was $508.0 million at Arcus Biosciences, down from $538.0 million in the prior quarter.
  • Over the last five years, Total Liabilities for RCUS hit a ceiling of $750.4 million in Q4 2021 and a floor of $270.3 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $638.0 million (2022), compared with a mean of $589.7 million.
  • Biggest five-year swings in Total Liabilities: skyrocketed 661.36% in 2021 and later dropped 26.8% in 2025.
  • Arcus Biosciences' Total Liabilities stood at $750.4 million in 2021, then dropped by 14.32% to $643.0 million in 2022, then fell by 1.56% to $633.0 million in 2023, then grew by 5.06% to $665.0 million in 2024, then fell by 23.61% to $508.0 million in 2025.
  • The last three reported values for Total Liabilities were $508.0 million (Q4 2025), $538.0 million (Q3 2025), and $526.0 million (Q2 2025) per Business Quant data.